n 2022, the U.S. Food and Drug Administration (FDA) granted its first approval for the use of organoid and organ-on-a-chip technologies in new drug development research, marking a milestone in the field of biomedical research.
In June 2024, the pen injector independently developed and produced by Wuxi NEST Biotechnology Co., Ltd. (hereinafter referred to as NEST) won the US Food and Drug Administration (FDA) 510 (k) Letter!
List
• Article Title：Engineered poly(A)-surrogates for translational regulation and therapeutic biocomputation in mammalian cells. • Author：Jiawei Shao
• Journal Title：Cell Research
• Impact Factor：44.1
• Article Title：Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours. Author：Qin Wang
• Journal Title：Nature Nanotechnology
• Impact Factor：38.3
XENOPIA INVESTMENT LTD, a standout distributor for NEST Biotechnology, has successfully obtained the Medical Device Registration Certificate for NEST’s laboratory supplies for cell cultivation in the country of Kenya.
